Document:

Exhibit 10.9

 

INVESTMENT AGREEMENT

 

THIS INVESTMENT AGREEMENT (this “Agreement”),
dated as of _____2021, is by and among (i) McLaren Technology Acquisition Corp.,
a Delaware corporation (the “SPAC”), (ii) McLaren Technology Acquisition Sponsor LLC, a Delaware limited liability
company (the “Sponsor”), and (iii) the investors listed on the signature pages hereto (“Investor”).
This Agreement may be executed by an investment manager on behalf of managed funds and/or accounts and for the elimination of doubt such
fund or account shall, severally and not jointly, be the Investor hereunder.

 

WHEREAS, in connection with the initial public
offering (the “IPO”) of units of the SPAC, Investor has expressed an interest in acquiring up to [ ] units in the IPO,
which shall not exceed 9.9% of the total outstanding shares of Class A common stock, par value $0.0001 per share (the “Class
A Common Stock”), underlying the units (not including the over-allotment option) (the “IPO Indication”),
at a price of $10.00 per unit.

 

WHEREAS, the parties wish to enter into this
Agreement pursuant to which Investor will purchase from the Sponsor Class B common stock, par value $0.0001 per share, of the SPAC (the
“Founder Shares”) for the same value paid by the Sponsor, or approximately $0.004 per share.

 

NOW THEREFORE, the parties hereto hereby agree
as follows:

 

Section 1. Sale and Purchase.

 

	 	(a)	In connection with the IPO Indication, and subject to the satisfaction of the conditions set forth in Section 1(b), the Sponsor hereby agrees to sell to Investor [ ] Founder Shares (such shares, the “Transferred Shares”) for an aggregate purchase price of $[ ] ($0.004 per share) (the “Transfer Price”) on the date of the closing of the IPO, and Investor hereby agrees to purchase the Transferred Shares (the “Transfer”). Concurrently with the Transfer, in consideration for the transfer of the Transferred Shares, Investor shall pay the Transfer Price to the Sponsor in immediately available funds.

 

	 	(b)	Subject to (i) the fulfillment by Investor (but
only to the extent actually allocated to Investor by the underwriters) of the IPO Indication (which shall include the acquisition of
100% of the units of the SPAC allocated to Investor by the underwriters in the IPO, which number of allocated units shall not be greater
than 9.9% of the units offered in the IPO (exclusive of any units that may be issued pursuant to the underwriters’ over-allotment option))
and (ii) Investor’s payment of the Transfer Price as contemplated by Section 1(a) of this Agreement, the Transfer shall occur
and be effective upon the closing of the IPO, automatically and without any action of any other party hereto. 

	 	 	 
	 	(c)	Notwithstanding anything to the contrary herein, both before and after the receipt of the Transferred Shares by the Investor, the number of Transferred Shares shall not be subject to cut-back, reduction, mandatory repurchase, redemption or forfeiture for any reason, including (i) transfer of the Founder Shares to any person, (ii) downsizing of the offering, (iii) failure of the underwriters to exercise their over-allotment option, (iv) concessions or “earn-out” triggers in connection with the negotiation of a Business Combination (as defined below), or (v) any other modification, without the Investor’s prior written consent.
	 	 	 
	 	(d)	The obligations of Investor hereunder are subject to there being no material change in structure, terms and conditions in the capital structure the SPAC from that set forth in the Registration Statement on Form S-1 filed with the United States Securities and Exchange Commission on _____, 2021, as amended (the “Registration Statement”).

 

    

     

    

 

Section 2. Representations and Warranties of the
SPAC. The SPAC hereby represents and warrants to Investor, as follows:

 

	 	(a)	The SPAC has full power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby.

 

	 	(b)	This Agreement has been duly and validly executed and delivered by the SPAC and constitutes a legal, valid and binding obligation of the SPAC enforceable against the SPAC in accordance with its terms.

 

	 	(c)	The execution and delivery of this Agreement, the consummation of the transactions contemplated hereby and the performance of its obligations hereunder will not materially conflict with, or result in any material violation of or default under, any agreement or other instrument to which the SPAC is a party or by which the SPAC is bound, or any decree, order, statute, rule or regulation applicable to the SPAC.

 

Section 3. Representations and Warranties of the
Sponsor. The Sponsor hereby represents and warrants to Investor, as follows:

 

	 	(a)	The Sponsor has full power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby.

 

	 	(b)	This Agreement has been duly and validly executed and delivered by the Sponsor and constitutes a legal, valid and binding obligation of the Sponsor enforceable against the Sponsor in accordance with its terms.

 

	 	(c)	The execution and delivery of this Agreement, the consummation of the transactions contemplated hereby and the performance of its obligations hereunder will not materially conflict with, or result in any material violation of or default under, any agreement or other instrument to which the Sponsor is a party or by which the Sponsor is bound, or any decree, order, statute, rule or regulation applicable to the Sponsor.
	 	 	 
	 	(d)	The terms set forth in this Agreement are as favorable to the Investor as the terms granted to all other investors entering into a similar agreement to purchase Founder Shares of the SPAC in connection with expressing interest in the IPO, provided that the Investor acknowledges that Founders Shares have been offered to the Sponsor, executive officers, advisors, directors and director nominees of the SPAC in connection with their service and the Sponsor expressly reserves the right to issue membership interests in the Sponsor its sole discretion.

 

Section 4. Representations and Warranties of
Investor. Investor hereby represents and warrants to the SPAC and the Sponsor, as follows:

 

	 	(a)	Investor has full power and authority to execute and deliver this Agreement and to perform its obligations hereunder.
	 	 	 
	 	(b)	This Agreement has been duly and validly executed and delivered by Investor and constitutes a legal, valid and binding obligation of Investor enforceable against Investor in accordance with its terms.
	 	 	 
	 	(c)	The execution and delivery of this Agreement, the consummation of the transactions contemplated hereby and the performance of its obligations hereunder will not materially conflict with, or result in any material violation of or default under, any agreement or other instrument to which Investor is a party or by which Investor is bound, or any decree, order, statute, rule or regulation applicable to Investor.

 

	 	(d)	Investor is an “accredited investor” as that term is defined in Regulation D promulgated under the Securities Act of 1933, as amended.
	 	 	 
	 	(e)	Investor has never been suspended or expelled from membership in any securities or commodities exchange or association or had a securities or commodities license or registration denied, suspended or revoked. Investor is not subject to or a respondent in any legal action for, any injunction, cease-and-desist order or order or stipulation to desist or refrain from any act or practice relating to the offering of securities in any jurisdiction; it, he or she has never been convicted of, or pleaded guilty to, any crime (i) involving fraud, (ii) relating to any financial transaction or handling of funds of another person, or (iii) pertaining to any dealings in any securities and it, he or she is not currently a defendant in any such criminal proceeding.

 

    2

     

    

 

Section 5. Additional Agreements and
Acknowledgements of Investor.

 

		(a)	Subject to Section 5(e), below, without written consent of
the SPAC and Sponsor, the Investor agrees not to transfer, assign or sell any Transferred Shares or the Class A Common Stock, issuable
upon conversion of the Transferred Shares held by it until the earlier of (i) one year after the date the SPAC consummates a Business
Combination and (ii) the earlier to occur of, subsequent to a Business Combination, (A) the first date on which the last reported sale
price of the Class A Common Stock equals or exceeds $12.00 per share of stock (as adjusted for stock sub-divisions, stock dividends,
reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days
after the consummation a Business Combination or (B) the date on which the SPAC consummates a subsequent liquidation, merger, stock exchange
or other similar transaction which results in all of the SPAC’s stockholders having the right to exchange their Class A Common Stock
for cash, securities or other property (the “Lock-Up Period”). The Transferred Shares shall not be bound by any additional
resale lock-up agreements with the SPAC or Sponsor, except as set forth in the Registration Statement. For the avoidance of doubt, this
Section 5 shall not restrict the Investor from transferring, assigning or selling any Class A Common Stock, warrants or units
acquired in the IPO or in the open market.   (b) Investor acknowledges that the SPAC was formed for the purpose of effecting a merger,
capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses
or entities (a “Business Combination”). Investor agrees with the SPAC that if the SPAC seeks stockholder approval
of a proposed Business Combination, then in connection with such proposed Business Combination, Investor shall vote all Founder Shares
in favor of such proposed Business Combination. Notwithstanding the foregoing, nothing shall prevent the Investor from seeking redemption
for any Class A Common Stock it acquires in the IPO or in the open market in accordance with the terms and conditions applicable to the
Class A Common Stock and the IPO described in the Registration Statement.   (c) Investor acknowledges that it is aware the SPAC
will establish a trust account (the “Trust Account”) for the benefit of its public stockholders upon the closing of
the IPO. Investor agrees that it has no right, title, interest or claim of any kind in or to any monies held in the Trust Account, or
any other asset of the SPAC as a result of any liquidation of the SPAC with respect to the Transferred Shares. The waiver of claim on
the assets of the SPAC shall not apply to any funds that have been released from the Trust Account other than such funds that have been
released pursuant to a shareholder redemption. For the avoidance of doubt, the foregoing waiver shall not apply to claims with respect
to any assets of the SPAC (including cash or otherwise) immediately following the consummation of its initial Business Combination.  
(d) In connection with the IPO, the SPAC shall enter into a registration rights agreement (the “Registration Rights Agreement”)
with the Sponsor, Investor and certain other parties thereto in the form filed as an exhibit to the SPAC’s Registration Statement. The
Registration Rights Agreement shall provide Investor with registration rights with respect to the Transferred Shares that are no less
favorable to Investor than the registration rights of the Sponsor set forth therein.   (e) The Investor may, prior to the expiration
of the Lock-Up Period, transfer the Transferred Shares to an affiliate of Investor so long as such affiliate executes and delivers to
the Company prior to such transfer a lock-up agreement on substantially similar terms as this Agreement with such lock-up obligation
of the affiliate transferee to be coterminous with the lock-up obligations of Investor.

 

    3

     

    

 

Section 6. Miscellaneous.

 

	 	(a)	Any notice or communication under this Agreement shall be in writing and given by (i) deposit in the United States mail, addressed to the party to be notified, postage prepaid and registered or certified with return receipt requested, (ii) recognized courier or overnight delivery service providing evidence of delivery, or (iii) transmission by hand delivery, electronic mail or facsimile, if to the Sponsor, to: McLaren Technology Acquisition Sponsor LLC, if to the SPAC, to: McLaren Technology Acquisition Corp., at their respective address or contact information as set forth in the Registration Statement or the exhibits attached thereto; and, if to the Investor, at the Investor’s address or contact information as set forth on the signature page attached hereto. The SPAC will not deliver any information which could restrict the Investor in trading of the securities of the SPAC or the post-merger company without the prior written consent of the Investor.
	 	 	 
	 	(b)	This Agreement shall be governed by the internal laws (and not the law of conflicts) of the State of New York.
	 	 	 
	 	(c)	This Agreement may not be amended, modified or waived without the written consent of the parties hereto.
	 	 	 
	 	(d)	The rights and obligations under this Agreement may not be assigned by any party hereto without the prior written consent of the other parties.
	 	 	 
	 	(e)	From time to time, at the reasonable request of any of the other parties hereto, each party hereto shall execute and deliver such additional documents and instruments and take such further lawful action as may be necessary to consummate and make effective, in the most expeditious manner practicable, the transactions contemplated by this Agreement. For U.S. federal income tax purposes, the parties agree to treat and report the purchase of the Class A Common Stock and the Founder Shares as a discounted bulk purchase of such shares by the Investor, and the Company agrees that it shall not treat or report the issuance of such Founder Shares to the Investor as a compensatory payment or fee.
	 	 	 
	 	(f)	Any term or provision of this Agreement which is invalid or unenforceable shall be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining rights of the person intended to be benefited by such provision or any other provisions of this Agreement.
	 	 	 
	 	(g)	This Agreement may be executed in two or more counterparts, each of which shall constitute an original, and all of which taken together shall constitute one and the same instrument. Any signature page delivered by a facsimile machine or electronic mail shall be binding to the same extent as an original signature page.

 

[Signature page follows]

 

    4

     

    

 

IN WITNESS WHEREOF, the undersigned have executed
this Agreement as of the date first written above.

 

	 	INVESTOR:
	 	 
	 	[	]
	 	 	 
	 	By:	 
	 	Name: 	[     ]
	 	Title:	[      ]
	 	 	Address:
	 	 	 
	 	 	Phone:
	 	 	 
	 	 	Email:

 

	 	SPAC:
	 	MCLAREN TECHNOLOGY ACQUISITION CORP.
	 	 	 
	 	By:	                   
	 	Name: 	 
	 	Title:	 

 

	 	SPONSOR:
	 	MCLAREN TECHNOLOGY ACQUISITION SPONSOR LLC
	 	 
	 	By:	               
	 	Name: 	 
	 	Title:	 

 

[Signature Page to Investment Agreement]

 

 

5EX-10.1

 Exhibit 10.1 

AMENDED AND RESTATED EMPLOYMENT AGREEMENT 

This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is hereby entered into to be effective from and
following September 1, 2021 (the “Effective Date”), between Tenet Healthcare Corporation (the “Company”) and Ronald A. Rittenmeyer (“Executive”). 

W I T N E S S E T H 

WHEREAS, the Company and Executive are party to that certain Employment Agreement, effective as of March 1, 2018, as amended on
February 27, 2019 and February 26, 2020 (the “Prior Agreement”); 
 WHEREAS, Executive is currently
serving as the Company’s Executive Chairman and Chief Executive Officer; 
 WHEREAS, in furtherance of the Company’s
long-term planned leadership succession transition, the Company and Executive desire to transition Executive’s role to Executive Chairman; and 

WHEREAS, the Company and Executive desire to enter into this Agreement as to the terms of Executive’s employment with the Company
from and after the Effective Date, which will supersede the Prior Agreement in its entirety effective as of the Effective Date. 
 NOW,
THEREFORE, in consideration of the foregoing, of the mutual promises contained herein and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 

1. Employment Term. The Company agrees to employ Executive pursuant to the terms of this Agreement, and Executive agrees to be so
employed, for a term commencing as of the Effective Date and ending on December 31, 2024 (the “Term”). Notwithstanding the foregoing, Executive’s employment hereunder may be earlier terminated in accordance with
Section 4 hereof. The period of time between the Effective Date and the termination of Executive’s employment hereunder shall be referred to herein as the “Employment Period.” 

2. Position and Duties. 

(a) During the portion of the Employment Period commencing on the Effective Date and ending on December 31, 2022 (the
“Initial Period”), Executive will serve as the Company’s Executive Chairman and Executive will report directly to the Board of Directors of the Company (the “Board”). During the Initial Period, Executive will
also serve as the Executive Chairman of the Board. During the portion of the Employment Period from and after January 1, 2023 (the “Subsequent Period”), Executive will serve as a senior advisor to the Chief Executive Officer
and the Board and perform senior-level advisory services as reasonably requested by the Chief Executive Officer and the Board for a period of time not to exceed eight (8) days per month. 

 (b) During the Initial Period, Executive shall have such responsibilities,
duties and authorities, and will render such services for the Company and its subsidiaries or affiliates as the Board may reasonably request from time to time. During the Initial Period, Executive will devote substantially all of Executive’s
business time, energy and efforts to Executive’s obligations hereunder and to the affairs of the Company; provided that the foregoing shall not prevent Executive from (i) serving on the boards of directors of non-profit organizations and, with the prior written approval of the Board, other for-profit companies, (ii) participating in charitable, civic, educational,
professional, community or industry affairs, (iii) managing Executive’s passive personal investments, (iv) serving on the board of directors of IQVIA Holdings, Inc., (v) serving on the executive board of the Cox School of
Business at Southern Methodist University, on the foundation board for the Church of Incarnation in Dallas, as a member of the U.S. Chamber of Commerce Board of Directors, and/or on the board of directors of the Federation of American Hospitals, and
(vi) providing advising services to Affina from time to time, so long as such activities in the aggregate do not interfere or conflict with Executive’s duties hereunder or create a potential business or fiduciary conflict. 

(c) During the Employment Period, Executive will be employed by Tenet Employment, Inc. for all purposes under this Agreement.

 3. Compensation and Benefits. 

(a) Base Salary. During the Initial Period, Executive shall receive an annual base salary (“Base
Salary”) equal to $1,500,000 per annum, payable by the Company in regular installments in accordance with the Company’s general payroll practices, less taxes and other applicable withholdings. During the Subsequent Period,
Executive’s shall receive an annual Base Salary equal to $750,000, payable by the Company in regular installments in accordance with the Company’s general payroll practices, less taxes and other applicable withholdings. 

(b) Annual Bonus. During the Initial Period, Executive shall be eligible to receive an annual incentive payment (the
“Annual Bonus”) based on a target bonus opportunity of no less than 150% of Executive’s Base Salary, with the actual Annual Bonus amount calculated based upon the attainment of one or more performance-based objectives
established by the Board or the Human Resources Committee thereof (the “Committee”) in its sole discretion. The Annual Bonus shall be subject to the terms and conditions of the annual bonus plan adopted by the Board or the
Committee, under which bonuses are generally payable to senior executives of the Company. The Annual Bonus shall be paid to Executive at the same time as annual bonuses are generally payable to other senior executives of the Company, subject to
Executive’s continuous employment through the applicable payment date, except as otherwise set forth in this Agreement. Notwithstanding anything herein to the contrary, the Board or Committee may grant Executive discretionary bonuses from time
to time in its sole and absolute discretion. 

  
 2 

 (c) Equity and Other Long-Term Incentive Awards. All equity and other
long-term incentive awards granted to Executive prior to the Effective Date (collectively, the “Long-Term Incentive Awards”) shall remain in full force and effect in accordance with the documents evidencing such awards
(including, without limitation, the Prior Agreement). During the Initial Period, Executive shall continue to be eligible to receive equity and other long-term incentive awards under any applicable plan adopted by the Company during the Employment
Period for which employees are generally eligible. The actual level of Executive’s participation in any such plan, if any, and the terms and conditions of any award granted under such plan shall be determined in the sole discretion of the Board
or Committee from time to time provided that such terms and conditions shall not be inconsistent with the terms of this Agreement. 

(d) Retention Bonus. Subject to Executive’s continued employment with the Company through the expiration of the
Term, Executive shall be entitled to receive a cash bonus in amount equal to $5,000,000 (the “Retention Bonus”), payable, less taxes and applicable withholdings, on the last day of the Term. Except as explicitly set forth below,
Executive shall have no further rights in respect of the Retention Bonus in the event that his employment with the Company is terminated prior to the expiration of the Term. 

(e) Employee Benefits. In addition, during the Employment Period, Executive shall be entitled to participate in the
Company’s benefits generally available to executive-level employees and on the same relative terms, including, for the avoidance of doubt, the Company’s health and welfare plans (including, without limitation, life and disability plans),
401(k) retirement savings plan, the Company’s Executive Retirement Account, and any other benefits in which Executive currently participates, subject, in each case, to the eligibility and participation requirements thereof; provided,
however, that Executive shall not participate in any severance plan or policy maintained by the Company for the benefit of senior executives. 

(f) Expenses; Certain Perquisites. During the Employment Period, the Company shall reimburse Executive for all
reasonable out-of-pocket expenses incurred by him in the course of performing his duties and responsibilities under this Agreement which are consistent with the
Company’s policies in effect from time to time with respect to travel, entertainment and other business expenses, subject to the Company’s requirements with respect to reporting and documentation of such expenses. In addition, during the
Employment Period, Executive will be entitled to use of the Company’s airplane for business and personal use (personal use not to exceed one hundred (100) hours per calendar year) without reimbursement to the Company in accordance with the
Company’s policies as in effect from time to time and consistent with past practice. 
 4. Termination. 

(a) The Employment Period shall terminate upon the first to occur of the following: 

(i) upon the conclusion of the Term; 

(ii) upon advance written notice of Executive’s voluntary resignation with Good Reason; 

(iii) immediately upon Executive’s death or Disability; 

  
 3 

 (iv) immediately upon a termination by the Company for Cause; or 

(v) immediately upon written notice by the Company without Cause or upon thirty (30) days’ advance written notice by
Executive without Good Reason (the date of such terminations set forth in (i) through (v) herein, the “Termination Date”). 

Unless otherwise determined by mutual agreement between Executive and the Board prior to the termination of Executive’s employment
pursuant to Sections 4(a)(i) through (v) herein, effective automatically as of any such Termination Date and without any further action taken by Executive, Executive will be deemed to effectively resign from all
positions, offices and directorships with the Company and any affiliate and subsidiary of the Company, as well as from any positions, offices and directorships on the Company’s and its affiliates and subsidiaries’ foundations, benefit
plans and programs. 
 (b) Death; Disability. Executive’s employment and the Employment Period shall terminate
automatically upon Executive’s death. The Company may terminate Executive’s employment and the Employment Period immediately upon the occurrence of a Disability, such termination to be effective upon Executive’s receipt of written
notice of such termination. Upon Executive’s death, or in the event that Executive’s employment and the Employment Period ends on account of Executive’s Disability, Executive or Executive’s estate, as applicable, shall be
entitled to the following: 
 (i) any accrued but unpaid Base Salary through the Termination Date, payable no later than ten
(10) days following the Termination Date; 
 (ii) reimbursement for any unreimbursed business expenses incurred through
the Termination Date in accordance with Section 3(f) of this Agreement, payable in accordance with applicable Company plan or policy; 

(iii) all other payments, benefits or fringe benefits to which Executive shall be entitled under the terms of any applicable
compensation arrangement or benefit, equity or fringe benefit plan or program or grant payable in accordance with the applicable Company plan, policy or award agreement (the payments described in (i), (ii), and (iii) hereof, collectively, the
“Accrued Benefits”); 
 (iv) a lump sum payment equal to the amount of Executive’s Base Salary that
remains payable to Executive during the Term, measured from the Termination Date through the end of the Term (the “Cash Payment”); such payment to be made on the first regularly scheduled payroll period following the Termination
Date; 
 (v) any Annual Bonus for any preceding fiscal year during the Initial Period which, as of the Termination Date, has
not been paid, and which would have been paid but for Executive’s termination of employment, such Annual Bonus to be paid at the same time as annual bonuses for such fiscal year are generally payable to other senior executives of the Company
(the “Prior Year Bonus”); 

  
 4 

 (vi) if the Termination Date occurs during the Initial Period, a pro-rata portion of the Annual Bonus Executive would have earned for the performance year in which the Termination Date occurs based on actual performance, with such pro-rata
portion determined based on the quotient determined by dividing the number of days between the beginning of the performance period in which such termination occurs and the Termination Date, divided by 365 (the
“Pro-Rata Annual Bonus”), which amount shall be paid at such time annual bonuses are paid to other senior executives of the Company; 

(vii) if the Termination Date occurs during the Initial Period, a lump sum payment equal to the sum of (x) a pro-rata portion of the Annual Bonus Executive would have earned for the performance year in which Termination Date occurs based on the higher of actual or target performance, with such pro-rata portion determined based on the quotient determined by dividing the number of days between the Termination Date and the conclusion of the performance period in which such termination occurs, divided by 365
(the “Pro-Rata Target Bonus”), and (y) a pro-rata portion of the Annual Bonus for any performance year remaining during the Initial Period that
begins following the Termination Date based on target performance, with such pro-rata portion determined based on the quotient determined by dividing the number of days between the beginning of the performance
year and the conclusion of the Term, divided by 365 (the “Pro-Rata Remaining Bonus”), payable on the first regularly scheduled payroll period following the Termination Date; 

(viii) effective as of the Termination Date, accelerated vesting of all equity and other Long-Term Incentive Awards held by
Executive (the “Accelerated Vesting”), which will be settled within thirty (30) days following Executive’s Termination Date. 

(ix) a lump sum cash payment in an amount equal to the Retention Bonus (the “Retention Bonus Acceleration”),
payable no later than ten (10) days following the Termination Date; and 
 (x) continued coverage for Executive and his
covered dependents under the Company’s health and welfare plans (including, without limitation, life and disability plans) and entitlement to any other benefits or perquisites in effect as of the Termination Date through the expiration of the
Term that would have applied had Executive’s employment continued for the duration of the Term (the “Continued Benefits”). Following the conclusion of the Term, Executive and his covered dependents shall be eligible to elect
continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) at Executive’s sole cost and expense. 

Following any such termination of Executive’s employment, except as set forth in this Section 4(b), Executive
shall have no further rights to any compensation or any other benefits under this Agreement. 

  
 5 

 (c) Termination by the Company for Cause; Resignation by Executive
without Good Reason. The Company may terminate Executive’s employment at any time for Cause and Executive may terminate his employment at any time without Good Reason upon thirty (30) days’ advance written notice to the Company.
If Executive’s employment is terminated by the Company for Cause or if Executive resigns without Good Reason, Executive shall be entitled to only the Accrued Benefits. 

(d) Termination by the Company without Cause; Resignation by Executive with Good Reason. The Company may terminate
Executive’s employment at any time without Cause, effective upon delivery to Executive of written notice in accordance with Section 4(a)(v), and Executive may voluntarily resign employment with the Company with Good
Reason (as defined below). In the event that Executive’s employment is terminated by the Company without Cause (other than due to death or Disability), or Executive voluntarily resigns with Good Reason, subject to
Section 4(f) (other than with respect to Section 4(d)(i)), Executive shall be entitled to: 

(i) the Accrued Benefits; 

(ii) the Cash Payment, payable on the first regularly scheduled payroll period following the Release Effective Date; 

(iii) payment of any Prior Year Bonus; 

(iv) payment of the Pro-Rata Annual Bonus; 

(v) payment of the Pro-Rata Target Bonus, and the
Pro-Rata Remaining Bonus, payable on the first regularly scheduled payroll period following the Release Effective Date; 

(vi) the Accelerated Vesting; 

(vii) the Retention Bonus Acceleration, payable on the first regularly scheduled payroll period following the Release Effective
Date; and 
 (viii) the Continued Benefits. 

(e) Termination upon the Conclusion of the Term. Executive’s employment will terminate automatically upon the
conclusion of the Term. Upon Executive’s termination of employment upon the conclusion of the Term, Executive shall only be entitled to only the Accrued Benefits. 

Following the termination of Executive’s employment by the Company without Cause or by Executive with Good Reason or upon the conclusion
of the Term, except as set forth in Section 4(d) or Section 4(e) hereof, Executive shall have no further rights to any compensation or any other benefits under this Agreement. Payments and benefits
provided in Section 4(d) or Section 4(e) shall be in lieu of any termination or severance payments or benefits for which Executive may be eligible under any of the plans, policies or programs of
the Company or under the Worker Adjustment Retraining Notification Act of 1988 or any similar state statute or regulation. 

  
 6 

 (f) Release of Claims, Continued Compliance. Notwithstanding any
provision herein to the contrary, the payment of any amount or provision of any benefit (other than the Accrued Benefits) pursuant to Section 4(d) (collectively, the “Severance Benefits”) shall be
conditioned upon Executive’s execution, delivery to the Company, and non-revocation of the release of claims in the form attached hereto as Exhibit A (and the expiration of any revocation period
contained in such release of claims) within sixty (60) days following the Termination Date (the date on which the release becomes effective and no longer subject to revocation, the “Release Effective Date”). The Company shall
also execute, and deliver to Executive, the release of claims in the form attached as Exhibit A simultaneously with the Release Effective Date, subject to the occurrence of the Release Effective Date. Any delay in the payment of the Severance
Benefits shall not extend the period of time that the Severance Benefits are payable. If Executive fails to execute the release of claims in such a timely manner so as to permit any revocation period to expire prior to the end of such sixty (60)-day period, or timely revokes Executive’s such release following its execution, Executive shall not be entitled to any of the Severance Benefits. If Executive materially breaches any obligation set forth
in Section 7 below and fails to cure such breach (if curable) after notice and a reasonable opportunity to cure, Executive’s right to receive the Severance Benefits shall immediately cease and be forfeited, and any
payment of the Severance Benefits previously paid to Executive shall be immediately repaid by Executive to the Company, if and to the extent such breach damages the Company as determined by a court of competent jurisdiction. 

5. Code Section 280G. To the extent that any amount payable to Executive hereunder, when combined with any other
payment or benefit (collectively, the “Payments”, which shall include, without limitation, the vesting of any equity awards or other non-cash benefit or property) that could be considered a
“parachute payment,” as such term is defined under Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”), exceed the limitations of Section 280G of the Code such that an excise tax will be
imposed under Section 4999 of the Code, the Payments shall be either (a) reduced (but not below zero) so that the present value of such total Payments received by Executive will be one dollar ($1.00) less than three times Executive’s
“base amount” (as defined in Section 280G(b)(3) of the Code) and so that no portion of such Payments received by Executive shall be subject to the excise tax imposed by Section 4999 of the Code, such parachute payments shall be
reduced in the following order: (a) any Pro-Rata Target Bonus, Pro-Rata Annual Bonus, Prior Year Bonus or Pro-Rata Remaining
Bonus, (b) any continuation of Base Salary (c) any other cash amounts payable to Executive (including the Retention Bonus), (d) any benefits continuation valued as parachute payments, and (e) any accelerated vesting of any equity
awards, or (b) paid in full, whichever of (a) or (b) produces the better net after tax position to Executive (taking into account any applicable excise tax under Section 4999 of the Code and any other applicable taxes). For purposes
of making the calculations and determinations required by this Section 5, the Company may engage an independent accounting firm or independent counsel to make such determinations, which shall be conclusive and binding on
the Company and Executive, and such independent accounting firm or independent counsel may rely on reasonable, good faith assumptions and approximations concerning the applicable of Section 280G and Section 4999 of the Code. 

  
 7 

 6. Selected Definitions. 

(a) “Cause” shall mean a termination of Executive’s employment by the Company due to any of the
following: (i) embezzlement, theft or other willful and material misappropriation by Executive of any Company property; (ii) Executive’s willful and material breach of any fiduciary duty to the Company or any of its subsidiaries;
(iii) Executive’s willful and material failure or refusal to comply with laws or regulations applicable to Company and its business, or the policies of the Company governing the conduct of its employees that causes material harm to the
Company; (iv) commission by Executive of a felony or of any crime involving moral turpitude, fraud, or misrepresentation; (v) the willful and material failure or refusal of Executive to perform his reasonably assigned job duties in
accordance with Company policy; or (vi) any gross negligence or willful misconduct of Executive resulting in a material loss to the Company, or material damage to the reputation of the Company. For purposes of this definition, no act or failure
to act on the part of Executive shall be deemed “willful” if it was undertaken in reasonable reliance on the advice of counsel or at the instruction of the Company, including but not limited to the Board or a committee of the Board of the
Company, or was due primarily to an error in judgment or negligence, but shall be deemed “willful” only if done or omitted to be done by Executive not in good faith and without reasonable belief that Executive’s action or omission was
in the best interest of the Company. Further, a failure to meet or exceed business objectives, as defined by the Company, will not constitute Cause, so long Executive devotes his reasonable efforts and attention to the achievement of those
objectives. 
 (b) “Disability” shall be defined as the inability of Executive to have performed
Executive’s material duties hereunder due to a physical or mental injury, infirmity or incapacity for one hundred eighty (180) days (including weekends and holidays) in any 365-day period as
determined by the Board in its reasonable discretion. 
 (c) “Good Reason” shall mean a termination of
Executive’s employment by Executive within 30 days of the Company’s failure to cure, in accordance with the procedures set forth below, any of the following events: (i) a reduction in any of Executive’s compensation rights set
forth in Section 3 hereof; (ii) failure to elect or reelect Executive as a member of the Board of Directors during the Initial Period, (iii) the removal of Executive by the Company from the position of Executive Chairman during the
Initial Period; (iv) a material reduction in Executive’s duties and responsibilities as in effect immediately prior to such reduction, except as explicitly contemplated hereunder following the Initial Period; (v) the assignment to
Executive of duties that are materially inconsistent with his then-current position(s) or the grant of duties that materially impair Executive’s ability to function in such position(s); (vi) relocation of Executive’s principal office to a
location that is more than fifty (50) miles outside of downtown Dallas, TX; (vii) during the Employment Period, individuals who, as of the Effective Date, constitute the Board, and any new director (other than a director whose initial
assumption of office occurs as a result of either an actual or threatened election contest (as such term is used in Rule 14a-11 of Regulation 14A promulgated under the Securities Exchange Act of 1934, as
amended) or other actual or threatened solicitation of proxies or consents by or on behalf of a person other than the Board) whose election by the Board or nomination for election by the 

  
 8 

 
Company’s stockholders was approved by a vote of at least 50% of the directors then still in office who either were directors as of the Effective Date or whose election or nomination for
election was previously so approved, cease for any reason to constitute at least a majority of the Board; or (viii) a material breach of any material provision of this Agreement by the Company. A termination hereunder shall not be treated as a
termination for Good Reason (x) if Executive shall have consented in writing to the occurrence of the event giving rise to the claim of termination for Good Reason, or (y) unless Executive shall have delivered a written notice to the Board
within three months of his having actual knowledge of the occurrence of one of such events stating that he intends to terminate his employment for Good Reason and specifying the factual basis for such termination, and such event, if capable of being
cured, shall not have been cured within 30 days of the receipt of such notice. 
 7. Restrictive Covenants 

(a) Confidentiality. During the course of Executive’s employment with the Company, Executive will have access to
Confidential Information. For purposes of this Agreement, “Confidential Information” means all data, information, ideas, concepts, discoveries, trade secrets, inventions (whether or not patentable or reduced to practice),
innovations, improvements, know-how, developments, techniques, methods, processes, treatments, drawings, sketches, specifications, designs, plans, patterns, models, plans and strategies, and all other
confidential or proprietary information or trade secrets in any form or medium (whether merely remembered or embodied in a tangible or intangible form or medium) whether now or hereafter existing, relating to or arising from the past, current or
potential business, activities and/or operations of the Company or any of its affiliates, including, without limitation, any such information relating to or concerning finances, sales, marketing, advertising, transition, promotions, pricing,
personnel, customers, suppliers, vendors, raw partners and/or competitors. Executive agrees that Executive shall not, directly or indirectly, use, make available, sell, disclose or otherwise communicate to any person, other than in the course of
Executive’s assigned duties and for the benefit of the Company, either during the period of Executive’s employment or at any time thereafter, any Confidential Information or other confidential or proprietary information received from third
parties subject to a duty on the Company’s and its subsidiaries’ and affiliates’ part to maintain the confidentiality of such information, and to use such information only for certain limited purposes, in each case, which shall have
been obtained by Executive during Executive’s employment by the Company (or any predecessor). The foregoing shall not apply to information that (i) was known to the public prior to its disclosure to Executive; (ii) becomes generally
known to the public subsequent to disclosure to Executive through no wrongful act of Executive or any representative of Executive; or (iii) Executive is required to disclose by applicable law, regulation or legal process (provided that
Executive provides the Company with prior notice of the contemplated disclosure and cooperates with the Company at its expense in seeking a protective order or other appropriate protection of such information). Nothing contained in this Agreement
shall be construed to prohibit Executive from reporting possible violations of federal or state law or regulation to any governmental agency or regulatory body or making other disclosures that are protected under any whistleblower provisions of
federal or state law or regulation, or from filing a charge with or participating in any investigation or proceeding conducted by any governmental agency or regulatory body. 

  
 9 

 (b) Noncompetition; Nonsolicitation. 

(i) During the Employment Period and for a period of two (2) years following the Termination Date (the “Restricted
Period”), Executive will not, directly or indirectly, own, manage, operate, control, be employed by (whether as an employee, consultant, independent contractor or otherwise, and whether or not for compensation) or render services to any
person, firm, corporation or other entity, in whatever form, engaged in competition with the Company or any of its subsidiaries or affiliates or in any other material business in which the Company or any of its subsidiaries or affiliates is engaged
on the date of termination or in which they have planned, on or prior to such date, to be engaged in on or after such date, in any locale of any country in which the Company conducts business. Notwithstanding the foregoing, nothing herein shall
prohibit Executive from being a passive owner of not more than one percent (1%) of the equity securities of a publicly traded corporation engaged in a business that is in competition with the Company or any of its subsidiaries or affiliates, so long
as Executive has no active participation in the business of such corporation. In addition, the provisions of this Section 7(b)(i) shall not be violated by Executive commencing employment with a subsidiary, division or unit
of any entity that engages in a business in competition with the Company or any of its subsidiaries or affiliates so long as Executive and such subsidiary, division or unit does not engage in a business in competition with the Company or any of its
subsidiaries or affiliates. 
 (ii) During the Restricted Period, Executive agrees that Executive shall not, directly or
indirectly, individually or on behalf of any other person, firm, corporation or other entity, solicit, aid or induce any employee of the Company or any of its subsidiaries or affiliates to leave such employment or retention or to accept employment
with or render services to or with any other person, firm, corporation or other entity unaffiliated with the Company or take any action to materially assist or aid any other person, firm, corporation or other entity in identifying or soliciting any
such employee. An employee shall be deemed covered by this Section 7(b)(ii) while so employed or retained and for a period of six (6) months thereafter; provided, however, that the Company will, in good
faith, consider exempting any employee who was terminated by the Company or any of its subsidiaries or affiliates. 
 (c)
Nondisparagement. Executive agrees not to make negative comments or otherwise disparage the Company or its officers, directors, employees, shareholders, agents or products other than in the good faith performance of Executive’s duties to
the Company while Executive is employed by the Company, it being understood and agreed that disparagement does not include compliance with legal process or subpoenas to the extent only truthful statements are rendered in such compliance attempt,
statements in response to any inquiry from a court or regulatory body, or statements or comments in rebuttal of media stories or alleged media stories. The Company will instruct its board members and

  
 10 

 
senior executives not to make any negative comments or otherwise defame or disparage Executive to any third parties, except as required by law, it being understood and agreed that disparagement
does not include compliance with legal process or subpoenas to the extent only truthful statements are rendered in such compliance attempt, statements in response to any inquiry from a court or regulatory body, or statements or comments in rebuttal
of media stories or alleged media stories. 
 (d) Trade Secrets. 18 U.S.C. § 1833(b) provides: “An
individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that—(i) is made—(A) in confidence to a Federal, State, or local government official, either
directly or indirectly, or to an attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing
is made under seal.” Nothing in this Agreement is intended to conflict with 18 U.S.C. § 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by 18 U.S.C. § 1833(b). Accordingly, the parties to this
Agreement have the right to disclose in confidence trade secrets to federal, state, and local government officials, or to an attorney, for the sole purpose of reporting or investigating a suspected violation of law. The parties also have the right
to disclose trade secrets in a document filed in a lawsuit or other proceeding, but only if the filing is made under seal and protected from public disclosure. 

(e) Reasonableness of Restrictive Covenants. In signing this Agreement, Executive gives the Company assurance that
Executive has carefully read and considered all of the terms and conditions of this Agreement, including the restraints imposed under this Section 7 hereof. Executive agrees that these restraints are necessary for the
reasonable and proper protection of the Company and its affiliates and their Confidential Information and that each and every one of the restraints is reasonable in respect to subject matter, length of time and geographic area, and that these
restraints, individually or in the aggregate, will not prevent Executive from obtaining other suitable employment during the period in which Executive is bound by the restraints. Executive acknowledges that each of these covenants has a unique, very
substantial and immeasurable value to the Company and its affiliates and that Executive has sufficient assets and skills to provide a livelihood while such covenants remain in force. Executive further covenants that Executive will not challenge the
reasonableness or enforceability of any of the covenants set forth in this Section 7, and that Executive will reimburse the Company and its affiliates for all costs (including reasonable attorneys’ fees) incurred in
connection with any action to enforce any of the provisions of this Section 7 if either the Company and/or its affiliates is the prevailing party in such dispute or if Executive challenges the reasonableness or
enforceability of any of the provisions of this Section 7. If Executive is the prevailing party in any action or dispute to enforce any of the provisions of this Section 7 (but not, for the
avoidance of doubt, if Executive challenges the reasonableness or enforceability of any of the covenants set forth in this Section 7), the Company will reimburse Executive for all costs (including reasonable attorneys’
fees) incurred by him in connection with such action or dispute. It is also agreed that each of the Company’s affiliates will have the right to enforce all of Executive’s obligations to that affiliate under this Agreement, including
without limitation pursuant to this Section 7. 

  
 11 

 (f) Reformation. If it is determined by a court of competent
jurisdiction in any state that any restriction in this Section 7 is excessive in duration or scope or is unreasonable or unenforceable under applicable law, it is the intention of the parties that such restriction may be
modified or amended by the court to render it enforceable to the maximum extent permitted by the laws of that state. 
 (g)
Tolling. In the event of any violation of the provisions of this Section 7, Executive acknowledges and agrees that the post-termination restrictions contained in this Section 7(b) shall be
extended by a period of time equal to the period of such violation, it being the intention of the parties hereto that the running of the applicable post-termination restriction period shall be tolled during any period of such violation. 

8. Notices. Any notices provided for in this Agreement shall be in writing and shall be effective when delivered in person or deposited
in the United States mail, postage prepaid, and addressed to Executive at his last known address on the books of the Company or, in the case of the Company, to it at its principal place of business, attention of the Board (with a copy to the General
Counsel of the Company), or to such other address as either party may specify by notice to the other actually received. 
 9. Complete
Agreement. This Agreement embodies the complete agreement and understanding among Executive and the Company and its subsidiaries with respect to the subject matter hereof and, as of the Effective Date, shall supersede and preempt any prior
understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way other than the agreements referenced herein or any agreement which by its terms continues beyond
Executive’s termination of employment. 
 10. Indemnification. The Company hereby agrees to indemnify Executive and hold
Executive harmless to the extent provided under the By-Laws of the Company and any agreement between the Company and Executive (including, without limitation, the Indemnification Agreement between the Company
and Executive dated June 24, 2010), against and in respect of any and all actions, suits, proceedings, claims, demands, judgments, costs, expenses (including reasonable attorneys’ fees), losses and damages resulting from Executive’s
good faith performance of Executive’s duties and obligations to the Company. The Company shall cover Executive acting in his capacity as an officer or director of the Company or any of its affiliates or subsidiaries, under the directors’
and officers’ liability insurance policies maintained by the Company for the benefit of similarly situated current and former directors and officers. 

11. No Assignment. This Agreement is personal to each of the parties hereto, and no party may assign or delegate any right or
obligation hereunder without first obtaining the written consent of the other party hereto. 
 12. Counterparts; Delivery by Facsimile or
PDF. This Agreement may be executed in separate counterparts (including by facsimile or PDF signature pages), each of which is deemed to be an original and all of which taken together constitute one and the same agreement. This Agreement and any
amendments hereto, to the extent signed and delivered by means of a facsimile machine or PDF, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it
were the original signed version thereof delivered in person. 

  
 12 

 13. Withholding Taxes. The Company may withhold from any and all amounts payable to
Executive hereunder such federal, state and local taxes as may be required to be withheld pursuant to any applicable law or regulation. 

14. Governing Law. This Agreement shall be construed and enforced in accordance with, and all questions concerning the construction,
validity, interpretation and performance of this Agreement shall be governed by, the laws of the state of Texas without giving effect to provisions thereof regarding conflict of laws. 

15. Waiver of Jury Trial. THE PARTIES HERETO HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED
UPON OR ARISING OUT OF THIS AGREEMENT. THE PARTIES HERETO ALSO WAIVE ANY BOND OR SURETY OR SECURITY UPON SUCH BOND WHICH MIGHT, BUT FOR THIS WAIVER, BE REQUIRED OF THE OTHER PARTY. THE PARTIES HERETO ACKNOWLEDGE THAT THIS WAIVER IS A MATERIAL
INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY RELIED ON THE WAIVER IN ENTERING INTO THIS AGREEMENT AND THAT EACH WILL CONTINUE TO RELY ON THE WAIVER IN THEIR RELATED FUTURE DEALINGS. THE COMPANY AND EXECUTIVE FURTHER
WARRANT AND REPRESENT THAT EACH HAS REVIEWED THIS WAIVER WITH THEIR RESPECTIVE LEGAL COUNSEL, AND THAT EACH KNOWINGLY AND VOLUNTARILY WAIVES THEIR RESPECTIVE JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. THIS WAIVER IS IRREVOCABLE,
MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THE WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THE TRANSACTION
CONTEMPLATED HEREBY. IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT. 
 16.
Amendment and Waiver. Any provision of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course of conduct or course of dealing or failure or delay by any party hereto in
enforcing or exercising any of the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement or be deemed to be an implied waiver of any provision of this Agreement. 

17. Section 409A. 

(a) The intent of the parties is that payments and benefits under this Agreement comply with Internal Revenue Code
Section 409A and the regulations and guidance promulgated thereunder (collectively, “Code Section 409A”) and, accordingly, to the maximum extent permitted, this Agreement will be interpreted to be in
compliance therewith. To the extent that any provision hereof is modified in order to comply with Code Section 409A, such modification will be made in good faith and will, to the maximum extent reasonably possible, maintain the original intent
and economic benefit to Executive 

  
 13 

 
and the Company of the applicable provision without violating the provisions of Code Section 409A. To the extent that reimbursements or other in-kind
benefits under this Agreement constitute “nonqualified deferred compensation” for purposes of Code Section 409A, (a) all expenses or other reimbursements hereunder will be made on or prior to the last day of the taxable year
following the taxable year in which such expenses were incurred by Executive, (b) any right to reimbursement or in-kind benefits shall not be subject to liquidation or exchanges for another benefit, and
(c) no such reimbursement, expenses eligible for reimbursement, or in-kind benefits provided in any table year will in any way affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year. 
 (b) A termination of
employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment unless such termination is also a “separation
from service” within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a “termination,” “termination of employment” or like terms shall mean “separation from
service.” Notwithstanding anything to the contrary in this Agreement, if the Employee is deemed on the date of termination to be a “specified employee” within the meaning of that term under Code Section 409A(a)(2)(B), then with
regard to any payment or the provision of any benefit that is considered deferred compensation under Code Section 409A payable on account of a “separation from service,” such payment or benefit shall not be made or provided until the
date which is the earlier of (A) the expiration of the six (6)-month period measured from the date of such “separation from service” of the Employee, and (B) the date of the Employee’s death, to the extent required under
Code Section 409A. Upon the expiration of the foregoing delay period, all payments and benefits delayed pursuant to this Section 17(b) (whether they would have otherwise been payable in a single sum or in installments
in the absence of such delay) shall be paid or reimbursed to the Employee in a lump sum, and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them
herein. 
 (c) For purposes of Code Section 409A, the Employee’s right to receive any installment payments pursuant
to this Agreement shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a payment period with reference to a number of days, the actual date of payment within the
specified period shall be within the sole discretion of the Company. 
 (d) Notwithstanding any other provision of this
Agreement to the contrary, in no event shall any payment under this Agreement that constitutes “nonqualified deferred compensation” for purposes of Code Section 409A be subject to offset by any other amount unless otherwise permitted
by Code Section 409A. 
 18. Survival. The provisions contained in Sections 5, 7 through 11, 13, 14, 15 and 17 hereof shall
survive the termination or expiration of the Term and the Employee’s employment with the Company and shall be fully enforceable thereafter. 

*             *
            * 

  
 14 

 IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the
date written below. 
  

			
	TENET HEALTHCARE CORPORATION
		
	By:	 	/s/ Thomas W. Arnst
	Name:	 	Thomas W. Arnst
	Title: Executive Vice President, Chief Administrative Officer & General Counsel
	
	Date: August 31, 2021

 Accepted and Agreed: 
  

			
	/s/ Ronald A. Rittenmeyer
	Name: Ronald A. Rittenmeyer

 Date: August 31, 2021 

  
 [Signature page to
Ronald Rittemeyer Amended and Restated Employment Agreement] 

 EXHIBIT A 

YOU SHOULD CONSULT WITH AN ATTORNEY
BEFORE SIGNING THIS RELEASE OF CLAIMS. 

Release Agreement1 

1. In consideration of the payments and benefits (the “Severance Benefits”) set forth in
Section 4(d) of the Amended and Restated Employment Agreement effective as of September 1, 2021, by and between Ronald A. Rittenmeyer (the “Executive”) and TENET HEALTHCARE CORPORATION (the
“Company”) (the “Employment Agreement”) (each of the Executive and the Company, a “Party” and collectively, the “Parties”), the sufficiency of which the Executive acknowledges, the
Executive, with the intention of binding himself and his heirs, executors, administrators and assigns, does hereby release, remise, acquit and forever discharge the Company and each of its subsidiaries and affiliates (the “Company Affiliated
Group”), their present and former officers, directors, executives, shareholders, agents, attorneys, employees and employee benefit plans (and the fiduciaries thereof), and the successors, predecessors and assigns of each of the foregoing
(collectively, the “Company Released Parties”), of and from any and all claims, actions, causes of action, complaints, charges, demands, rights, damages, debts, sums of money, accounts, financial obligations, suits, expenses,
attorneys’ fees and liabilities of whatever kind or nature in law, equity or otherwise, whether accrued, absolute, contingent, unliquidated or otherwise and whether now known or unknown, suspected or unsuspected, which the Executive,
individually or as a member of a class, now has, owns or holds, or has at any time heretofore had, owned or held, arising on or prior to the date hereof (each, a “Claim”), against any Company Released Party, including without
limitation any Claim that arises out of, or relates to, (i) the Employment Agreement, the Executive’s employment with the Company or any of its subsidiaries and affiliates, or any termination of such employment, (ii) for severance or
vacation benefits, unpaid wages, salary or incentive payments, (iii) breach of contract, wrongful discharge, impairment of economic opportunity, defamation, intentional infliction of emotional harm or other tort, (iv) any violation of
applicable state and local labor and employment laws (including, without limitation, all laws concerning unlawful and unfair labor and employment practices) and/or (v) for employment discrimination under any applicable federal, state or
local statute, provision, order or regulation, and including, without limitation, any Claim under Title VII of the Civil Rights Act of 1964 (“Title VII”), the Civil Rights Act of 1988, the Fair Labor Standards Act, the Americans
with Disabilities Act (“ADA”), the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), the Age Discrimination in Employment Act (“ADEA”), the Texas Commission on Human Rights Act,
TX Labor Code § 21.001 et seq., the Texas Payday Law, TX Labor Code § 61.001 et seq., the Texas Minimum Wage Act, TX Labor Code § 62.001 et seq., and the Texas Communicable Disease Act, TX
Health and Safety Code § 81.101 et seq., all as amended, and any similar or analogous state statute, excepting only: 
  

	 	A.	 rights of the Executive to the Accrued Benefits and the Severance Benefits (as all such terms are defined in
the Employment Agreement); 

  

	1 	 Subject to update to reflect changes in law. 

  
 A-1 

	 	B.	 the right of the Executive to receive nondisparagement protection from the Company in accordance with
Section 7(c) of the Employment Agreement, and the Executive’s right to expense reimbursement from the Company in the amount of $[_____] in accordance with Sections 3(f) of the Employment Agreement; 

 

	 	C.	 the right of the Executive in respect of any outstanding equity or other long-term incentive awards in
accordance with the documents evidencing such awards; 

  

	 	D.	 the right of the Executive to receive COBRA continuation coverage in accordance with applicable law;

  

	 	E.	 the right of Executive to enforce the terms of this Release Agreement; 

 

	 	F.	 Claims for benefits under any health, disability, retirement, deferred compensation, life insurance or other
similar employee benefit plan (within the meaning of Section 3(3) of ERISA) of the Company Affiliated Group; and 

  

	 	G.	 rights to indemnification the Executive has or may have under an agreement with any member of the Company
Affiliated Group (including Section 10 of the Employment Agreement), the by-laws or certificate of incorporation of any member of the Company Affiliated Group, the Indemnification Agreement between the
Company and Executive dated June 24, 2010 or as an insured under any director’s and officer’s liability insurance policy now or previously in force, including any tail policy. 

In addition, nothing in this Release prevents Executive from filing, cooperating with, or participating in any proceeding before the Equal
Employment Opportunity Commission, the Securities and Exchange Commission, or the Department of Labor, except that Executive hereby waives his right to any monetary benefits in connection with any such Claim, charge or proceeding. Nothing contained
in this Agreement shall be construed to prohibit the Executive from reporting possible violations of federal or state law or regulation to any governmental agency or regulatory body or making other disclosures that are protected under any
whistleblower provisions of federal or state law or regulation, or from filing a charge with or participating in any investigation or proceeding conducted by any governmental agency or regulatory body. 

2. Pursuant to 18 U.S.C. § 1833(b), an individual may not be held criminally or civilly liable under any federal or state trade
secret law for the disclosure of a trade secret that: (i) is made (A) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney, and (B) solely for the purpose of reporting or
investigating a suspected violation of law or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Additionally, an individual who files a lawsuit for retaliation by an
employer for reporting a suspected violation of law may disclose a trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual: (A) files any document containing the trade
secret under seal and (B) does not disclose the trade secret except pursuant to court order. 
 3. The Executive acknowledges and
agrees that this Release is not to be construed in any way as an admission of any liability whatsoever by any Company Released Party, any such liability being expressly denied. The Company acknowledges and agrees that this Release is not to be
construed in any way as an admission of any liability whatsoever by the Executive, any such liability being expressly denied. 

  
 A-2 

 4. This Release applies to any relief no matter how called, including, without limitation,
wages, back pay, front pay, compensatory damages, liquidated damages, punitive damages, damages for pain or suffering, costs, and attorneys’ fees and expenses but does not apply to the Claims not released by the Executive in Section 1
above. 
 5. The Executive specifically acknowledges that his acceptance of the terms of this Release is, among other things, a specific
waiver of his Claims under Title VII, ADEA, ADA and any state or local law or regulation in respect of discrimination of any kind; provided, however, that nothing herein shall be deemed, nor does anything contained herein purport, to
be a waiver of any Claim which by law the Executive is not permitted to waive. 
 6. As to Claims arising under ADEA, the Executive
acknowledges that he been given a period of twenty-one (21) days to consider whether to execute this Release. If the Executive accepts the terms hereof and executes this Release, he may thereafter, for a
period of seven (7) days following (and not including) the date of execution, revoke this Release as it relates to the release of Claims arising under ADEA. If no such revocation occurs, this Release shall become irrevocable in its entirety,
and binding and enforceable against the Executive, on the day next following the day on which the foregoing seven-day period has elapsed (such date, the “ADEA Release Effective Date”). If such
a revocation occurs, the Executive shall irrevocably forfeit any right to payment of the Severance Benefits (other than $1,000 as consideration for the Claims that continue to be waived hereunder and his rights to be indemnified and covered under
any applicable directors’ and officers’ liability insurance policies) or any other cash severance, benefits continuation or other post-termination benefits pursuant to the Employment Agreement (other than rights to the Accrued Benefits (as
defined in the Employment Agreement) and any rights to be indemnified or covered under any applicable directors’ and officers’ liability insurance policies), but the remainder of the Employment Agreement shall continue in full force. 

7. Other than as to Claims arising under ADEA, this Release shall be immediately effective upon execution by the Executive. 

8. Release by the Company. Subject to the occurrence of the ADEA Release Effective Date, the Company, on behalf of itself and its
controlled subsidiaries, fully, finally and forever releases and discharges Executive and his heirs, executors, administrators, personal representatives, successors and assigns (“Executive Releasees”) from all Claims against
Executive arising prior to and through execution of this Release Agreement by the Company, including, without limitation (a) any Claims arising out of or relating to the Company’s employment with the Company and its affiliates or the
termination thereof, (b) any Claims arising from or in any way related to any agreement between Executive and the Company and its affiliates, and/or (c) any Claims arising from or in any way related to any awards, policies, plans, programs
or practices of the Company and its affiliates; provided, however, that this Section 8 is not intended to and shall not release or limit Claims (i) relating to the Executive’s restrictive covenant
obligations under Section 7 of the Employment Agreement and Section 7 of that certain Non-Qualified Stock Option Performance Awards agreement by and between the Company and Executive, dated
September 29, 2017, or (ii) seeking to enforce the terms of this Release Agreement. 

  
 A-3 

 9. The Executive acknowledges and agrees that he has not, with respect to any transaction or
state of facts existing prior to the date hereof, filed any complaints, charges or lawsuits against any Company Released Party with any governmental agency, court or tribunal. 

10. The Executive acknowledges that he has been advised to seek, and has had the opportunity to seek, the advice and assistance of an attorney
with regard to this Release, and has been given a sufficient period within which to consider this Release. 
 11. The Parties acknowledge
that this Release relates only to Claims that exist as of the date of this Release. 
 12. The Parties acknowledge that Sections 5, 7
through 11, 13, 14, 15 and 17 of the Employment Agreement shall survive the execution of this Release. 
 13. The Executive acknowledges
that the Severance Benefits he is receiving in connection with this Release and his obligations under this Release are in addition to anything of value to which the Executive is entitled from the Company. 

14. Each provision hereof is severable from this Release, and if one or more provisions hereof are declared invalid, the remaining provisions
shall nevertheless remain in full force and effect. If any provision of this Release is so broad, in scope, or duration or otherwise, as to be unenforceable, such provision shall be interpreted to be only so broad as is enforceable. 

15. This Release constitutes the complete agreement of the Parties in respect of the subject matter hereof and shall supersede all prior
agreements between the Parties in respect of the subject matter hereof except to the extent set forth herein. 
 16. The failure to enforce
at any time any of the provisions of this Release or to require at any time performance by another party of any of the provisions hereof shall in no way be construed to be a waiver of such provisions or to affect the validity of this Release, or any
part hereof, or the right of any party thereafter to enforce each and every such provision in accordance with the terms of this Release. 

17. This Release may be executed in several counterparts, each of which shall be deemed to be an original, but all of which together shall
constitute one and the same instrument. Signatures delivered by facsimile shall be deemed effective for all purposes. 
 18. This Release
shall be binding upon any and all successors and assigns of the Executive and the Company. 
 19. Except for issues or matters as to which
federal law is applicable, this Release shall be governed by and construed and enforced in accordance with the laws of the State of Delaware without giving effect to the conflicts of law principles thereof. 

*             *
            * 

  
 A-4 

 IN WITNESS WHEREOF, the Company has executed this Release as of the date written below. 

 

			
	 TENET HEALTHCARE CORPORATION

		
	 By:
	 	 
		 	 Name:

		 	 Title:

		
	 Date:
	 	 

 Accepted and Agreed: 

______________________ 
 Name:
Ronald A. Rittenmeyer 
 Date: ______________________ 

  
 [Signature page to
Release Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]